Omega Therapeutics IPO Presentation Deck

Ex vivo PoC in Monogenic Disease Program - Alopecia Downregulation of SFRP1 at 7 days post-treatment in primary human hair follicle dermal papilla (HFDP) cells %Change in expression 150 100 50 Untreated Negative control Controller 1 Controller 2 *Hawkshaw et. al. 2018 PLOS Biology 16(5): e2003705. © 2021 Omega Therapeutics, Inc. Therapeutic threshold* Controller 3 SFRP1 regulates intrafollicular canonical Wnt/ß-catenin activity in the human hair bulb Inhibiting SFRP1 activity has the potential to enhance hair shaft production, hair shaft keratin expression 27

View entire presentation